Related Experiment Video
Updated: Sep 10, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.0K
Managing heart failure with reduced ejection fraction (HFrEF): Integrating SGLT2 inhibitors
The Nurse Practitioner
|August 26, 2025
Summary
Managing heart failure with reduced ejection fraction (HFrEF) involves four drug classes. This article explores integrating sodium-glucose cotransporter-2 (SGLT2) inhibitors into HFrEF treatment, focusing on outpatient volume management challenges.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure with reduced ejection fraction (HFrEF) management has evolved significantly.
- Current guidelines recommend four drug classes: beta blockers, RAAS inhibitors, MRAs, and SGLT2 inhibitors.
- Clinicians are familiar with the first three classes but face challenges with SGLT2 inhibitors.
Purpose of the Study:
- To explore clinical considerations for integrating SGLT2 inhibitors into HFrEF treatment regimens.
- To address challenges associated with SGLT2 inhibitor use, particularly volume management.
- To provide guidance for outpatient management of HFrEF with complex pharmacologic regimens.
Main Methods:
- Review of current HFrEF treatment guidelines.
- Discussion of the role of SGLT2 inhibitors in HFrEF.
- Analysis of clinical challenges in outpatient SGLT2 inhibitor initiation and management.
- Focus on volume status assessment and management strategies.
Main Results:
- SGLT2 inhibitors represent a crucial addition to HFrEF pharmacotherapy.
- Volume management is a key consideration when initiating and titrating SGLT2 inhibitors.
- Successful integration requires careful patient assessment and monitoring.
- Optimizing HFrEF care involves understanding the interplay between different drug classes.
Conclusions:
- Integrating SGLT2 inhibitors into HFrEF treatment requires careful attention to volume management.
- Outpatient clinicians need strategies to effectively incorporate SGLT2 inhibitors into existing regimens.
- Further research and clinical experience will refine SGLT2 inhibitor use in HFrEF.
- Optimizing pharmacologic therapy is essential for improving left ventricular function in HFrEF.
Related Concept Videos
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32